Type of Treatment Impacts Recurrence in Laryngeal SCC

Share this content:
Type of Treatment Impacts Recurrence in Laryngeal SCC
Type of Treatment Impacts Recurrence in Laryngeal SCC

WEDNESDAY, Dec. 14, 2016 (HealthDay News) -- For patients with laryngeal squamous cell carcinoma (SCC), factors predictive of recurrence include neck metastasis at presentation and nonsurgical treatment, according to a study published online Nov. 30 in Head & Neck.

Aaro Haapaniemi, M.D., from Helsinki University Hospital in Finland, and colleagues analyzed a nationwide laryngeal SCC cohort from Finnish university hospitals during 2001 to 2005. Data were included for 316 patients with initial successful therapy.

The researchers found that 22 percent of patients had laryngeal SCC recurrence. The median time to recurrence was nine months, and 90 percent occurred within 36 months following treatment. Independent prognostic factors for recurrence included the World Health Organization performance status >0, neck metastasis at presentation, and nonsurgical treatment. Five-year overall survival was 53 percent for patients with local recurrence and 5 percent for patients with regional/distant recurrences. For glottic and nonglottic laryngeal SCC recurrence, overall survival was 45 and 0 percent, respectively.

"The type of treatment affected the risk of recurrence in this retrospective series. Local recurrences carried a chance for successful salvage treatment," the authors write. "Routine follow-up beyond 36 months remains controversial."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »